Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 285

1.

Chemical carcinogenicity revisited 2: Current knowledge of carcinogenesis shows that categorization as a carcinogen or non-carcinogen is not scientifically credible.

Doe JE, Boobis AR, Dellarco V, Fenner-Crisp PA, Moretto A, Pastoor TP, Schoeny RS, Seed JG, Wolf DC.

Regul Toxicol Pharmacol. 2019 Apr;103:124-129. doi: 10.1016/j.yrtph.2019.01.024. Epub 2019 Jan 18. Review.

2.

Chemical carcinogenicity revisited 1: A unified theory of carcinogenicity based on contemporary knowledge.

Wolf DC, Cohen SM, Boobis AR, Dellarco VL, Fenner-Crisp PA, Moretto A, Pastoor TP, Schoeny RS, Seed JG, Doe JE.

Regul Toxicol Pharmacol. 2019 Apr;103:86-92. doi: 10.1016/j.yrtph.2019.01.021. Epub 2019 Jan 8. Review.

3.

Chemical carcinogenicity revisited 3: Risk assessment of carcinogenic potential based on the current state of knowledge of carcinogenesis in humans.

Cohen SM, Boobis AR, Dellarco VL, Doe JE, Fenner-Crisp PA, Moretto A, Pastoor TP, Schoeny RS, Seed JG, Wolf DC.

Regul Toxicol Pharmacol. 2019 Apr;103:100-105. doi: 10.1016/j.yrtph.2019.01.017. Epub 2019 Jan 8. Review.

4.

Overview on legislation and scientific approaches for risk assessment of combined exposure to multiple chemicals: the potential EuroMix contribution.

Rotter S, Beronius A, Boobis AR, Hanberg A, van Klaveren J, Luijten M, Machera K, Nikolopoulou D, van der Voet H, Zilliacus J, Solecki R.

Crit Rev Toxicol. 2018 Oct;48(9):796-814. doi: 10.1080/10408444.2018.1541964. Epub 2019 Jan 10. Review.

PMID:
30632445
5.

Paracetamol metabolism, hepatotoxicity, biomarkers and therapeutic interventions: a perspective.

Athersuch TJ, Antoine DJ, Boobis AR, Coen M, Daly AK, Possamai L, Nicholson JK, Wilson ID.

Toxicol Res (Camb). 2018 Mar 6;7(3):347-357. doi: 10.1039/c7tx00340d. eCollection 2018 May 8. Review.

6.

Obfuscating transparency?

Aschner M, Autrup H, Berry CL, Boobis AR, Cohen SM, Dekant W, Galli CL, Goodman JI, Gori GB, Greim HA, Kaminski NE, Klaassen CD, Klaunig JE, Lotti M, Marquardt HW, Moretto A, Pelkonen O, Sipes IG, Wallace KB, Yamazaki H.

Regul Toxicol Pharmacol. 2018 Aug;97:A1-A3. doi: 10.1016/j.yrtph.2018.07.004. Epub 2018 Jul 11.

PMID:
30017904
7.

Benchmark dose (BMD) modeling: current practice, issues, and challenges.

Haber LT, Dourson ML, Allen BC, Hertzberg RC, Parker A, Vincent MJ, Maier A, Boobis AR.

Crit Rev Toxicol. 2018 May;48(5):387-415. doi: 10.1080/10408444.2018.1430121. Epub 2018 Mar 8. Review.

PMID:
29516780
8.

Thresholds of Toxicological Concern for cosmetics-related substances: New database, thresholds, and enrichment of chemical space.

Yang C, Barlow SM, Muldoon Jacobs KL, Vitcheva V, Boobis AR, Felter SP, Arvidson KB, Keller D, Cronin MTD, Enoch S, Worth A, Hollnagel HM.

Food Chem Toxicol. 2017 Nov;109(Pt 1):170-193. doi: 10.1016/j.fct.2017.08.043. Epub 2017 Sep 1.

9.

Response to Loomis et al Comment on Boobis et al.

Boobis AR, Cohen SM, Dellarco VL, Doe JE, Fenner-Crisp PA, Moretto A, Pastoor TP, Schoeny RS, Seed JG, Wolf DC.

Regul Toxicol Pharmacol. 2017 Aug;88:358-359. doi: 10.1016/j.yrtph.2017.02.011. Epub 2017 Feb 16. No abstract available.

PMID:
28212846
10.

Classification schemes for carcinogenicity based on hazard-identification have become outmoded and serve neither science nor society.

Boobis AR, Cohen SM, Dellarco VL, Doe JE, Fenner-Crisp PA, Moretto A, Pastoor TP, Schoeny RS, Seed JG, Wolf DC.

Regul Toxicol Pharmacol. 2016 Dec;82:158-166. doi: 10.1016/j.yrtph.2016.10.014. Epub 2016 Oct 22.

11.

Scientific principles for the identification of endocrine-disrupting chemicals: a consensus statement.

Solecki R, Kortenkamp A, Bergman Å, Chahoud I, Degen GH, Dietrich D, Greim H, Håkansson H, Hass U, Husoy T, Jacobs M, Jobling S, Mantovani A, Marx-Stoelting P, Piersma A, Ritz V, Slama R, Stahlmann R, van den Berg M, Zoeller RT, Boobis AR.

Arch Toxicol. 2017 Feb;91(2):1001-1006. doi: 10.1007/s00204-016-1866-9. Epub 2016 Oct 6.

12.

Upholding science in health, safety and environmental risk assessments and regulations.

Aschner M, Autrup HN, Berry SC, Boobis AR, Cohen SM, Creppy EE, Dekant W, Doull J, Galli CL, Goodman JI, Gori GB, Greim HA, Joudrier P, Kaminski NE, Klaassen CD, Klaunig JE, Lotti M, Marquardt HW, Pelkonen O, Sipes IG, Wallace KB, Yamazaki H.

Toxicology. 2016 Sep 14;371:12-16. doi: 10.1016/j.tox.2016.09.005. Epub 2016 Sep 14.

13.

Considering new methodologies in strategies for safety assessment of foods and food ingredients.

Blaauboer BJ, Boobis AR, Bradford B, Cockburn A, Constable A, Daneshian M, Edwards G, Garthoff JA, Jeffery B, Krul C, Schuermans J.

Food Chem Toxicol. 2016 May;91:19-35. doi: 10.1016/j.fct.2016.02.019. Epub 2016 Mar 3. Review.

14.

Effects of mid-respiratory chain inhibition on mitochondrial function in vitro and in vivo.

Broom AJ, Ambroso J, Brunori G, Burns AK, Armitage JR, Francis I, Gandhi M, Peterson RA, Gant TW, Boobis AR, Lyon JJ.

Toxicol Res (Camb). 2015 Sep 17;5(1):136-150. doi: 10.1039/c5tx00197h. eCollection 2016 Jan 1.

15.

Towards microbial fermentation metabolites as markers for health benefits of prebiotics.

Verbeke KA, Boobis AR, Chiodini A, Edwards CA, Franck A, Kleerebezem M, Nauta A, Raes J, van Tol EA, Tuohy KM.

Nutr Res Rev. 2015 Jun;28(1):42-66. doi: 10.1017/S0954422415000037. Review.

16.

E2F1-mediated FOS induction in arsenic trioxide-induced cellular transformation: effects of global H3K9 hypoacetylation and promoter-specific hyperacetylation in vitro.

Rahman S, Housein Z, Dabrowska A, Mayán MD, Boobis AR, Hajji N.

Environ Health Perspect. 2015 May;123(5):484-92. doi: 10.1289/ehp.1408302. Epub 2015 Jan 9.

17.

Interleukin-6 mediated upregulation of CYP1B1 and CYP2E1 in colorectal cancer involves DNA methylation, miR27b and STAT3.

Patel SA, Bhambra U, Charalambous MP, David RM, Edwards RJ, Lightfoot T, Boobis AR, Gooderham NJ.

Br J Cancer. 2014 Dec 9;111(12):2287-96. doi: 10.1038/bjc.2014.540. Epub 2014 Oct 21.

18.

The use of mode of action information in risk assessment: quantitative key events/dose-response framework for modeling the dose-response for key events.

Simon TW, Simons SS Jr, Preston RJ, Boobis AR, Cohen SM, Doerrer NG, Fenner-Crisp PA, McMullin TS, McQueen CA, Rowlands JC; RISK21 Dose-Response Subteam.

Crit Rev Toxicol. 2014 Aug;44 Suppl 3:17-43. doi: 10.3109/10408444.2014.931925. Review.

PMID:
25070415
19.

Risk assessment in the 21st century: roadmap and matrix.

Embry MR, Bachman AN, Bell DR, Boobis AR, Cohen SM, Dellarco M, Dewhurst IC, Doerrer NG, Hines RN, Moretto A, Pastoor TP, Phillips RD, Rowlands JC, Tanir JY, Wolf DC, Doe JE.

Crit Rev Toxicol. 2014 Aug;44 Suppl 3:6-16. doi: 10.3109/10408444.2014.931924. Review.

PMID:
25070414
20.

A 21st century roadmap for human health risk assessment.

Pastoor TP, Bachman AN, Bell DR, Cohen SM, Dellarco M, Dewhurst IC, Doe JE, Doerrer NG, Embry MR, Hines RN, Moretto A, Phillips RD, Rowlands JC, Tanir JY, Wolf DC, Boobis AR.

Crit Rev Toxicol. 2014 Aug;44 Suppl 3:1-5. doi: 10.3109/10408444.2014.931923. Review.

PMID:
25070413
21.

Systems toxicology: from basic research to risk assessment.

Sturla SJ, Boobis AR, FitzGerald RE, Hoeng J, Kavlock RJ, Schirmer K, Whelan M, Wilks MF, Peitsch MC.

Chem Res Toxicol. 2014 Mar 17;27(3):314-29. doi: 10.1021/tx400410s. Epub 2014 Jan 21.

22.

Elucidation of toxicity pathways in lung epithelial cells induced by silicon dioxide nanoparticles.

Okoturo-Evans O, Dybowska A, Valsami-Jones E, Cupitt J, Gierula M, Boobis AR, Edwards RJ.

PLoS One. 2013 Sep 4;8(9):e72363. doi: 10.1371/journal.pone.0072363. eCollection 2013.

23.

Evaluation of the utility of the lifetime mouse bioassay in the identification of cancer hazards for humans.

Osimitz TG, Droege W, Boobis AR, Lake BG.

Food Chem Toxicol. 2013 Oct;60:550-62. doi: 10.1016/j.fct.2013.08.020. Epub 2013 Aug 15. Review.

PMID:
23954551
24.

Global food supply. Reevaluate pesticides for food security and safety.

Verger PJ, Boobis AR.

Science. 2013 Aug 16;341(6147):717-8. doi: 10.1126/science.1241572. No abstract available.

PMID:
23950515
25.

A proposed framework for assessing risk from less-than-lifetime exposures to carcinogens.

Felter SP, Conolly RB, Bercu JP, Bolger PM, Boobis AR, Bos PM, Carthew P, Doerrer NG, Goodman JI, Harrouk WA, Kirkland DJ, Lau SS, Llewellyn GC, Preston RJ, Schoeny R, Schnatter AR, Tritscher A, van Velsen F, Williams GM.

Crit Rev Toxicol. 2011 Jul;41(6):507-44. doi: 10.3109/10408444.2011.552063. Epub 2011 May 18. Review.

PMID:
21591905
26.

Human risk assessment of heavy metals: principles and applications.

Dorne JL, Kass GE, Bordajandi LR, Amzal B, Bertelsen U, Castoldi AF, Heppner C, Eskola M, Fabiansson S, Ferrari P, Scaravelli E, Dogliotti E, Fuerst P, Boobis AR, Verger P.

Met Ions Life Sci. 2011;8:27-60.

PMID:
21473375
27.

Risk assessment of combined exposure to multiple chemicals: A WHO/IPCS framework.

Meek ME, Boobis AR, Crofton KM, Heinemeyer G, Raaij MV, Vickers C.

Regul Toxicol Pharmacol. 2011 Apr 2. [Epub ahead of print]

28.

Application of the TTC concept to unknown substances found in analysis of foods.

Koster S, Boobis AR, Cubberley R, Hollnagel HM, Richling E, Wildemann T, Würtzen G, Galli CL.

Food Chem Toxicol. 2011 Aug;49(8):1643-60. doi: 10.1016/j.fct.2011.03.049. Epub 2011 Mar 30. Review.

29.

Using mode of action information to improve regulatory decision-making: an ECETOC/ILSI RF/HESI workshop overview.

Carmichael N, Bausen M, Boobis AR, Cohen SM, Embry M, Fruijtier-Pölloth C, Greim H, Lewis R, Bette Meek ME, Mellor H, Vickers C, Doe J.

Crit Rev Toxicol. 2011 Mar;41(3):175-86. doi: 10.3109/10408444.2010.541225. Review.

PMID:
21401325
30.

Food and Chemical Toxicology publishes papers that further scientific understanding of issues of public concern.

Boobis AR.

Food Chem Toxicol. 2010 Mar;48(3):771. doi: 10.1016/j.fct.2010.01.022. Epub 2010 Jan 25. No abstract available.

PMID:
20102731
31.

Mode of action considerations in the quantitative assessment of tumour responses in the liver.

Boobis AR.

Basic Clin Pharmacol Toxicol. 2010 Mar;106(3):173-9. doi: 10.1111/j.1742-7843.2009.00505.x. Epub 2009 Dec 17. Review.

32.

Influence of operating parameters on the biodegradation of steroid estrogens and nonylphenolic compounds during biological wastewater treatment processes.

Koh YK, Chiu TY, Boobis AR, Scrimshaw MD, Bagnall JP, Soares A, Pollard S, Cartmell E, Lester JN.

Environ Sci Technol. 2009 Sep 1;43(17):6646-54.

PMID:
19764230
33.

A data-based assessment of alternative strategies for identification of potential human cancer hazards.

Boobis AR, Cohen SM, Doerrer NG, Galloway SM, Haley PJ, Hard GC, Hess FG, Macdonald JS, Thibault S, Wolf DC, Wright J.

Toxicol Pathol. 2009 Oct;37(6):714-32. doi: 10.1177/0192623309343779. Epub 2009 Aug 21.

PMID:
19700658
34.

Application of key events analysis to chemical carcinogens and noncarcinogens.

Boobis AR, Daston GP, Preston RJ, Olin SS.

Crit Rev Food Sci Nutr. 2009 Sep;49(8):690-707. doi: 10.1080/10408390903098673.

35.

The Key Events Dose-Response Framework: a cross-disciplinary mode-of-action based approach to examining dose-response and thresholds.

Julien E, Boobis AR, Olin SS; Ilsi Research Foundation Threshold Working Group.

Crit Rev Food Sci Nutr. 2009 Sep;49(8):682-9. doi: 10.1080/10408390903110692.

36.

Increased expression of histone proteins during estrogen-mediated cell proliferation.

Zhu Z, Edwards RJ, Boobis AR.

Environ Health Perspect. 2009 Jun;117(6):928-34. doi: 10.1289/ehp.0800109. Epub 2009 Feb 7.

37.

Effects of pharmaceuticals and other active chemicals at biological targets: mechanisms, interactions, and integration into PB-PK/PD models.

Kapitulnik J, Pelkonen O, Gundert-Remy U, Dahl SG, Boobis AR.

Expert Opin Ther Targets. 2009 Jul;13(7):867-87. doi: 10.1517/14728220903018965. Review.

PMID:
19530989
38.

The significance of sample mass in the analysis of steroid estrogens in sewage sludges and the derivation of partition coefficients in wastewaters.

Chiu TY, Koh YK, Paterakis N, Boobis AR, Cartmell E, Richards KH, Lester JN, Scrimshaw MD.

J Chromatogr A. 2009 Jun 12;1216(24):4923-6. doi: 10.1016/j.chroma.2009.04.019. Epub 2009 Apr 15.

PMID:
19426986
39.

Re: Guyton, Kathryn Z., Barone, Stanley, Jr., Brown, Rebecca C., Euling, Susan Y., Jinot, Jennifer, Makris, Susan (2008). Mode of action frameworks: a critical analysis. Journal of Toxicology and Environmental Health, Part B, 11(1): 16-31.

Meek ME, Berry C, Boobis AR, Cohen SM, Hartley M, Munn S, Olin S, Schlatter J, Vickers C.

J Toxicol Environ Health B Crit Rev. 2008 Oct;11(8):681-3; author reply 684-5. doi: 10.1080/10937400801985648. No abstract available.

PMID:
18821425
40.

Local kinetics and dynamics of xenobiotics.

Pelkonen O, Kapitulnik J, Gundert-Remy U, Boobis AR, Stockis A.

Crit Rev Toxicol. 2008;38(8):697-720. doi: 10.1080/10408440802194931 . Review.

PMID:
18686076
41.

Proteomic analysis of human breast cell lines using SELDI-TOF MS shows that mixtures of estrogenic compounds exhibit simple similar action (concentration additivity).

Zhu Z, Edwards RJ, Boobis AR.

Toxicol Lett. 2008 Sep 26;181(2):93-103. doi: 10.1016/j.toxlet.2008.07.006. Epub 2008 Jul 15.

PMID:
18675332
42.

A sensitive and robust method for the determination of alkylphenol polyethoxylates and their carboxylic acids and their transformation in a trickling filter wastewater treatment plant.

Koh YK, Chiu TY, Boobis AR, Cartmell E, Pollard SJ, Scrimshaw MD, Lester JN.

Chemosphere. 2008 Sep;73(4):551-6. doi: 10.1016/j.chemosphere.2008.06.016. Epub 2008 Jul 25.

PMID:
18657288
43.

Cumulative risk assessment of pesticide residues in food.

Boobis AR, Ossendorp BC, Banasiak U, Hamey PY, Sebestyen I, Moretto A.

Toxicol Lett. 2008 Aug 15;180(2):137-50. doi: 10.1016/j.toxlet.2008.06.004. Epub 2008 Jun 8. Review.

PMID:
18585444
44.

Identification of estrogen-responsive proteins in MCF-7 human breast cancer cells using label-free quantitative proteomics.

Zhu Z, Boobis AR, Edwards RJ.

Proteomics. 2008 May;8(10):1987-2005. doi: 10.1002/pmic.200700901.

PMID:
18491314
45.

Testicular dysgenesis syndrome and the estrogen hypothesis: a quantitative meta-analysis.

Martin OV, Shialis T, Lester JN, Scrimshaw MD, Boobis AR, Voulvoulis N.

Environ Health Perspect. 2008 Feb;116(2):149-57. doi: 10.1289/ehp.10545. Review.

46.

IPCS framework for analyzing the relevance of a noncancer mode of action for humans.

Boobis AR, Doe JE, Heinrich-Hirsch B, Meek ME, Munn S, Ruchirawat M, Schlatter J, Seed J, Vickers C.

Crit Rev Toxicol. 2008;38(2):87-96. doi: 10.1080/10408440701749421. Review.

PMID:
18259981
47.

Risk assessment of dietary supplements.

Boobis AR.

Novartis Found Symp. 2007;282:3-25; discussion 25-8, 212-8. Review.

PMID:
17913221
49.

C-terminal antibodies (CTAbs): a simple and broadly applicable approach for the rapid generation of protein-specific antibodies with predefined specificity.

Edwards RJ, Wrigley A, Bai Z, Bateman M, Russell H, Murray S, Lu H, Taylor GW, Boobis AR, Sriskandan S.

Proteomics. 2007 May;7(9):1364-72.

PMID:
17407178
50.

Expression of cytochromes P450 3A and P-glycoprotein in human large intestine in paired tumour and normal samples.

Canaparo R, Nordmark A, Finnström N, Lundgren S, Seidegård J, Jeppsson B, Edwards RJ, Boobis AR, Rane A.

Basic Clin Pharmacol Toxicol. 2007 Apr;100(4):240-8.

Supplemental Content

Loading ...
Support Center